Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.5
2.7
Journals
Applied Sciences
Special Issues
New Research Trends in Hematology and Cancerous Tumours
share announcement

New Research Trends in Hematology and Cancerous Tumours

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".

Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 7472

Special Issue Editor

Dr. Philipp Bernhard Staber

E-Mail Website
Guest Editor
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Australia
Interests: hematology; lymphoma

Special Issue Information

Dear Colleagues,

Blood/hematologic cancers begin in blood-forming tissues (e.g., bone marrow，lymph system, and blood cells) and were once considered incurable cancers. Thanks to modern-day management, patients with hematologic cancers are seeing remissions and living longer, or even achieving cures. New clinical and scientific findings lead to the advancement in diagnosis and treatment of blood cancers and the development of more efficacious and less toxic therapeutic approaches. We are now at a position where we need to develop these findings into preclinical and clinical outcomes and therefore, we provide a platform for prompt communication of original and innovative research findings associated to blood cancers.

This Special Issue welcomes submissions presented in the form of original, review, and case report articles related to hematologic cancers.

Potential topics include, but are not limited to:

  •  Leukemia
  •  Lymphoma
  •  Myeloma
  •  Molecular Diagnosis
  •  Blood Cancer Diagnosis and Staging

Dr. Philipp Bernhard Staber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Leukemia
  • Lymphoma
  • Myeloma
  • Molecular Diagnosis
  • Blood Cancer Diagnosis and Staging

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 15359 KiB  
Article
Immunohistochemical Expression Patterns of Tight Junction Proteins, Pro-Apoptotic and Anti-Apoptotic Factors on Progression of Intestinal Mucositis of Onco-Hematological Patients under Epirubicin-Based Chemotherapy
by Coralia Cotoraci, Alciona Sasu, Eftimie Miutescu, Dana Iovanescu, Sami Gharbia, Alina Ciceu, Hildegard Herman and Anca Hermenean
Appl. Sci. 2021, 11(10), 4710; https://doi.org/10.3390/app11104710 - 20 May 2021
Viewed by 1989
Abstract
Chemotherapy and radiation are often accompanied by complications such as intestinal mucositis. The aim of this study was to assess by immunohistochemical assay the consequences of epirubicin-based therapy applied to onco-hematological patients, on the mucosal cells that undergo apoptosis and on the tight [...] Read more.
Chemotherapy and radiation are often accompanied by complications such as intestinal mucositis. The aim of this study was to assess by immunohistochemical assay the consequences of epirubicin-based therapy applied to onco-hematological patients, on the mucosal cells that undergo apoptosis and on the tight junction proteins, immediately before and after a short time of chemotherapy administration. We assessed the protein expression and distribution of the pro-apoptotic Bax, anti-apoptotic Bcl-2 and effector Caspase-3 as key proteins in apoptosis pathways and the changes in immunopositivity of Claudin-1 and ZO-1 tight junction proteins. Results show that the Bcl-2 family is involved in intestinal damage via Caspase-3 dependent apoptosis of epithelial cells. Additionally, the intestinal mucositis activates other injurious pathways through a dramatic drop in Claudin-1 and ZO-1 expressions, contributing for a while to a structural and functional integrity disruption of the intestinal epithelium. Full article
(This article belongs to the Special Issue New Research Trends in Hematology and Cancerous Tumours)
►▼ Show Figures

Figure 1

Review

Jump to: Research

41 pages, 7984 KiB  
Review
Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma
by Coralia Cotoraci, Alina Ciceu, Alciona Sasu, Eftimie Miutescu and Anca Hermenean
Appl. Sci. 2021, 11(10), 4451; https://doi.org/10.3390/app11104451 - 13 May 2021
Cited by 1 | Viewed by 4044
Abstract
Multiple myeloma (MM) is one of the most widespread hematological cancers. It is characterized by a clonal proliferation of malignant plasma cells in the bone marrow and by the overproduction of monoclonal proteins. In recent years, the survival rate of patients with multiple [...] Read more.
Multiple myeloma (MM) is one of the most widespread hematological cancers. It is characterized by a clonal proliferation of malignant plasma cells in the bone marrow and by the overproduction of monoclonal proteins. In recent years, the survival rate of patients with multiple myeloma has increased significantly due to the use of transplanted stem cells and of the new therapeutic agents that have significantly increased the survival rate, but it still cannot be completely cured and therefore the development of new therapeutic products is needed. Moreover, many patients have various side effects and face the development of drug resistance to current therapies. The purpose of this review is to highlight the bioactive active compounds (flavonoids) and herbal extracts which target dysregulated signaling pathway in MM, assessed by in vitro and in vivo experiments or clinical studies, in order to explore their healing potential targeting multiple myeloma. Mechanistically, they demonstrated the ability to promote cell cycle blockage and apoptosis or autophagy in cancer cells, as well as inhibition of proliferation/migration/tumor progression, inhibition of angiogenesis in the tumor vascular network. Current research provides valuable new information about the ability of flavonoids to enhance the apoptotic effects of antineoplastic drugs, thus providing viable therapeutic options based on combining conventional and non-conventional therapies in MM therapeutic protocols. Full article
(This article belongs to the Special Issue New Research Trends in Hematology and Cancerous Tumours)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop